NCT03896724View on ClinicalTrials.gov

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

R21 adjuvanted with 25mcg Matrix-M

Vaccine

BIOLOGICAL

Rabies Vaccine

Vaccine

BIOLOGICAL

R21 adjuvanted with 50mcg Matrix-M

vaccine

Trial Locations (1)

Unknown

Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro

All Listed Sponsors
collaborator

Institut de Recherche en Sciences de la Sante, Burkina Faso

OTHER_GOV

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER

NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso | Biotech Hunter | Biotech Hunter